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The glycolytic enzyme α-enolase is a highly conserved protein involved in multiple functions 
(Díaz-Ramos A et al 2012). Besides the mainly cytoplasmic localization, the protein has been 
detected on the surface of prokaryotic and eukaryotic cells where it functions as a plasminogen 
receptor, while  a shorter variant, called Myc promoter-binding protein-1 (MBP-1), is mainly 
located in the nucleus. 
Several lines of evidence indicate that  MBP-1 acts as a tumor suppressor, negatively regulating cell 
proliferation or promoting apoptosis of cancer cells. Although a few reports indicate that stressful 
conditions, such as glucose deprivation or hypoxia, may modulate MBP-1 expression in 
mammalian cells the putative signaling pathway(s) underlying MBP-1 expression still remains 
largely elusive.  
On the other hand, elevated expression of α-enolase has been observed in many tumor types and its 
surface expression has been reported in lung, pancreatic and breast cancer cells. The involvement of 
surface α-enolase in invasion and metastasis has recently been demonstrated in lung cancer (Hsia 
K-C et al 2013), nevertheless the molecular mechanisms of its transport from cytoplasm to cell 
membrane are still object of hypothesis and speculative models  (Didiasova M et al 2014). 
Since either the nuclear or the surface function of α-enolase may be potential target of novel 
therapeutic approaches in cancer, the present study was aimed at the identification of the signaling 
pathways  involved in these alternative functions. 
To dissect the pathways leading to MBP-1 expression, we used a breast cancer cell line, SKBr3, and 
293T cells that ectopically overexpress α-enolase/MBP-1. We demonstrate that the glycolysis 
inhibitor 2-Deoxyglucose and the ER stress inducing drug Thapsigargin promote MBP-1 expression 
through the AKT, PERK, eIF2 signalling axis.  
In order to investigate how α-enolase moves to cell surface and to identify the signaling pathways 
involved in this process, we stimulated non tumorigenic mammary epithelial cells and breast cancer 
cells with receptor ligands and analyzed the variation in the level of surface α-enolase using  
biochemical assays and immunolabeling techniques. We show that Epidermal growth factor (EGF) 
and pro-inflammatory endotoxin Lipopolysaccharide (LPS) treatments up regulate the cell-surface 
expression of α-enolase through interaction with their receptors, EGFR and TLR 4, respectively. 
Moreover, we partially dissected the putative signaling pathways underlying α-enolase translocation 
to cell membrane in mammary epithelial and breast cancer cells, suggesting the involvement of 
MAPK/ERK and Src pathways. 
Our results contribute to shed light on the molecular mechanisms regulating MBP-1 and surface α-
enolase expression in normal and cancer cells. 
